|
[Related PubMed/MEDLINE]
Total Number of Papers: 257
|
|
|
|
|
[Display Entries]
|
|
|
| |
|
[Entries Per Page]
|
|
per page
|
| |
|
Page Control
|
|
|
|
Page: of
|
|
|
|
| Abbreviation |
: EASL |
| Long Form |
: European Association for the Study of the Liver |
|
| No. |
Year |
Title |
Co-occurring Abbreviation |
| 1 |
2022 |
Comparison of MRI-based response criteria and radiomics for the prediction of early response to transarterial radioembolization in patients with hepatocellular carcinoma. |
HCC, mRECIST, MRI, ROC, TARE |
| 2 |
2022 |
Early Treatment Consideration in Patients with Hepatitis B 'e' Antigen-Positive Chronic Infection: Is It Time for a Paradigm Shift? |
CHB, HBeAg, HCC |
| 3 |
2022 |
New Liver MR Imaging Hallmarks for Small Hepatocellular Carcinoma Screening and Diagnosing in High-Risk Patients. |
ECA, HBSC, HCC |
| 4 |
2022 |
Reliability of extracellular contrast versus gadoxetic acid in assessing small liver lesions using liver imaging reporting and data system v.2018 and European association for the study of the liver criteria. |
ECAs, GA, LI-RADS |
| 5 |
2022 |
Setting Up a Local Registry to Improve the Care of Patients With Primary Biliary Cholangitis. |
BSG, PBC |
| 6 |
2022 |
Simplifying Treatment Criteria in Chronic Hepatitis B: Reducing Barriers to Elimination. |
AASLD, AATA, APASL, CHB, HBV |
| 7 |
2021 |
A consensus integrated care pathway for patients with primary biliary cholangitis: a guideline-based approach to clinical care of patients. |
PBC |
| 8 |
2021 |
Advances in treatment and prevention of hepatitis B. |
AASLD, APASL, CHB |
| 9 |
2021 |
Anti-HEV IgG Avidity Testing: Utility for Diagnosing Acute and Resolved Genotype 3 Infections. |
GT3 |
| 10 |
2021 |
Brazilian Society of Hepatology and Brazilian College of Radiology practice guidance for the use of elastography in liver diseases. |
ALEH, SBH |
| 11 |
2021 |
Comparison of LI-RADS with other non-invasive liver MRI criteria and radiological opinion for diagnosing hepatocellular carcinoma in cirrhotic livers using gadoxetic acid with histopathological explant correlation. |
APASL, HCC, JSH, LI-RADS, MRI, OPTN, PPV |
| 12 |
2021 |
Comparison of the current guidelines for diagnosing hepatocellular carcinoma using gadoxetic acid-enhanced magnetic resonance imaging. |
APASL, CI, HCCs, KLCSG-NCC, LI-RADS, MRI |
| 13 |
2021 |
COVID-19 in Chronic Liver Disease and Liver Transplantation: A Clinical Review. |
AASLD, APASL, COVID-19 |
| 14 |
2021 |
Demographics, Biochemical Characteristics, and Phases of Chronic Hepatitis B Virus Infection: Retrospective Analysis From a Secondary Care Setup. |
ALT, DAAs, DCLD, HBV, phases II and IV |
| 15 |
2021 |
Estimating the attributable fraction of cirrhosis and hepatocellular carcinoma due to hepatitis B and C. |
ECDC, HCC |
| 16 |
2021 |
Evaluation of Five International HBV Treatment Guidelines: Recommendation for Resource-Limited Developing Countries Based on the National Study in Nepal. |
AASLD, APASL, AST, HBV, NICE, WHO |
| 17 |
2021 |
Evaluation of the Relationship between Insulin Resistance and HBV DNA Level in Patients with HBeAg-negative Chronic HBV Infection (Natural Course Phase 3). |
BMI, CHB, GGT, HBV, HDL, HOMA-IR, TG, USG, VLDL |
| 18 |
2021 |
Evidence-based clinical practice guidelines for liver cirrhosis 2020. |
AASLD, ASH/NASH, BQs, CQs, FRQs, JSGE, JSH |
| 19 |
2021 |
Evidence-based clinical practice guidelines for Liver Cirrhosis 2020. |
AASLD, ASH/NASH, BQs, CQs, FRQs, JSGE, JSH |
| 20 |
2021 |
Hepatitis E: Genotypes, strategies to prevent and manage, and the existing knowledge gaps. |
HEV, WHO |
| 21 |
2021 |
Lipiodol as an intra-procedural imaging biomarker for liver tumor response to transarterial chemoembolization: Post-hoc analysis of a prospective clinical trial. |
cTACE, mOS, mRECIST |
| 22 |
2021 |
Non-invasive imaging criteria for the diagnosis of hepatocellular carcinoma in non-cirrhotic patients with chronic hepatitis B. |
HCC, LI-RADS, TIV |
| 23 |
2021 |
Predictors and outcome of emergent Liver transplantation for patients with acute-on-chronic liver failure. |
ACLF, CLIF-SOFA, LT, MELD |
| 24 |
2021 |
Prevalence of drug-drug interactions with pangenotypic direct-acting antivirals for hepatitis C and real-world care management in the United States: a retrospective observational study. |
AASLD, DAA, DDIs, GLE-PIB, HCV, SOF-VEL |
| 25 |
2021 |
Scoping review of clinical practice guidelines on the management of benign liver tumours. |
ACG, AGREE II, BLT, FNH, HCA, PRISMA |
| 26 |
2021 |
Therapeutic plasma exchange in children with acute liver failure (ALF): is it time for incorporation into the ALF armamentarium? |
ALF, PALF |
| 27 |
2021 |
Widespread gaps in the quality of care for primary biliary cholangitis in UK. |
PBC, UDCA |
| 28 |
2021 |
[The European Association for the Study of Liver (EASL) nutrition guidelines.] |
--- |
| 29 |
2020 |
2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights. |
AASLD, BCLC, CNLC, HBV, HCC, ICIs, TACE |
| 30 |
2020 |
Alcohol-related liver diseases (ALD). |
ALD, AUD |
| 31 |
2020 |
Alcohol-related liver diseases. |
--- |
| 32 |
2020 |
Chronic hepatitis B in children, report of a single-centre longitudinal study on 152 children. |
HBV |
| 33 |
2020 |
Comparative study on guidelines in determining HBV phases in Iranian patients. |
AASLD, ACG, APASL, HBV |
| 34 |
2020 |
Comparison of guidelines for diagnosis of hepatocellular carcinoma using gadoxetic acid-enhanced MRI in transplantation candidates. |
AASLD, APASL, KLCA-NCC, MC |
| 35 |
2020 |
Comparison of the diagnostic performance of imaging criteria for HCCs ≤ 3.0cm on gadoxetate disodium-enhanced MRI. |
APASL, HCC, KLCA-NCC, LI-RADS, MRI |
| 36 |
2020 |
EASL clinical practice guidelines for the management of occupational liver diseases. |
CPG, OLD |
| 37 |
2020 |
Eligibility for hepatitis B antiviral therapy among adults in the general population in Zambia. |
aOR, ART, AUROC, AVT, CI, HBsAg, HBV, WHO |
| 38 |
2020 |
Empirical 188Re-HDD/lipiodol intra-arterial therapy based on tumor volume, in patients with solitary inoperable hepatocellular carcinoma. |
AFP, CECT, HCC, RECIST, SPECT-CT |
| 39 |
2020 |
Hepatitis B: Who to treat? A critical review of international guidelines. |
AASLD, APASL, HCC, WHO |
| 40 |
2020 |
How Much Liver Tissue Is Required for Sufficient Histological Staging in Patients with Primary Biliary Cholangitis? |
ARFI, MLFS, PBC |
| 41 |
2020 |
Infection deteriorating hepatitis B virus related acute-on-chronic liver failure: a retrospective cohort study. |
ACLF, HBV-ACLF |
| 42 |
2020 |
Prediction of overall survival in patients with hepatocellular carcinoma treated with Y-90 radioembolization by imaging response criteria. |
BCLC, HCC, HR, mRECIST, qEASL, RECIST, TARE, vRECIST |
| 43 |
2020 |
Reasons to consider early treatment in chronic hepatitis B patients. |
CHB, HBeAg, HCC |
| 44 |
2020 |
Role of Contrast-Enhanced Ultrasound as a Second-Line Diagnostic Modality in Noninvasive Diagnostic Algorithms for Hepatocellular Carcinoma. |
APHE, CEUS, HCC, KLCA-NCC |
| 45 |
2020 |
Safety and Efficacy of Segmental Yttrium-90 Radioembolization for Hepatocellular Carcinoma after Transjugular Intrahepatic Portosystemic Shunt Creation. |
HCC, OLT, OS, TIPS, TTP, WHO |
| 46 |
2020 |
Screening for non-alcoholic fatty liver disease in type 2 diabetes using non-invasive scores and association with diabetic complications. |
AER, AST, CKD, CVD, FIB-4, FLI, NAFLD, NFS |
| 47 |
2020 |
Screening strategies for nonalcoholic fatty liver disease in type 2 diabetes: Insights from NHANES 2005-2016. |
NAFLD, NHANES, T2DM |
| 48 |
2020 |
Spontaneous Bacterial Peritonitis: We Are Still Behind. |
AASLD, SBP |
| 49 |
2020 |
[Several issues worthy of reference and discussion of 2019 edition of the European Association for the Study of the Liver guideline for drug-induced liver injury]. |
DILI |
| 50 |
2019 |
Alcohol-Related Liver Disease: Areas of Consensus, Unmet Needs and Opportunities for Further Study. |
AASLD |
| 51 |
2019 |
Alcohol-related liver disease: Areas of consensus, unmet needs and opportunities for further study. |
AASLD |
| 52 |
2019 |
Alpha-fetoprotein assessment for hepatocellular carcinoma after transarterial chemoembolization. |
HCC, HR, OS, TACE |
| 53 |
2019 |
Clinical practice guidelines in Wilson disease. |
AASLD, ALF, ESPGHAN, WD |
| 54 |
2019 |
Clinical presentations of Hepatitis E: A clinical review with representative case histories. |
BTS, HEV |
| 55 |
2019 |
Comparison of international guidelines for noninvasive diagnosis of hepatocellular carcinoma: 2018 update. |
AASLD, APASL, HCC, KLCA-NCC, LI-RADS, MRI |
| 56 |
2019 |
Complications constitute a major risk factor for mortality in hepatitis B virus-related acute-on-chronic liver failure patients: a multi-national study from the Asia-Pacific region. |
AARC, AARC-ACLFs, CLIF-C OFs, CLIF-C-ACLFs, COSSH-ACLFs, HBV-ACLF, MELDs, TPPMs |
| 57 |
2019 |
Emerging Role of Hepatobiliary Magnetic Resonance Contrast Media and Contrast-Enhanced Ultrasound for Noninvasive Diagnosis of Hepatocellular Carcinoma: Emphasis on Recent Updates in Major Guidelines. |
CEUS, CT, HCC, KLCA-NCC, MRI |
| 58 |
2019 |
First-Line Selective Internal Radiation Therapy in Patients with Uveal Melanoma Metastatic to the Liver. |
HR, SIRT |
| 59 |
2019 |
Incidence and Mortality of Acute-on-Chronic Liver Failure Using Two Definitions in Patients with Compensated Cirrhosis. |
ACLF, APASL, CI |
| 60 |
2019 |
Joint Consensus Statement of the Indian National Association for Study of the Liverand Indian Radiological and Imaging Associationfor the Diagnosis and Imaging of Hepatocellular CarcinomaIncorporating Liver Imaging Reporting and Data System. |
AASLD, HCC |
| 61 |
2019 |
Local Tumor Control and Patient Outcome Using Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: iRECIST as a Potential Substitute for Traditional Criteria. |
HCC, iRECIST, mRECIST, RECIST 1.1, SBRT, WHO |
| 62 |
2019 |
Man or machine? Prospective comparison of the version 2018 EASL, LI-RADS criteria and a radiomics model to diagnose hepatocellular carcinoma. |
AUCs, HBV, HCC, LI-RADS, MR |
| 63 |
2019 |
Radiomics machine-learning signature for diagnosis of hepatocellular carcinoma in cirrhotic patients with indeterminate liver nodules. |
AUC, HCC, pts |
| 64 |
2019 |
Retrospective comparison of EASL 2018 and LI-RADS 2018 for the noninvasive diagnosis of hepatocellular carcinoma using magnetic resonance imaging. |
HCC, LI-RADS, MRI |
| 65 |
2019 |
Screening, diagnosis and risks associated with Hepatitis E virus infection. |
HEV |
| 66 |
2019 |
The risk of hepatocellular carcinoma among chronic hepatitis B virus-infected patients outside current treatment criteria. |
AASLD, APASL, HCC |
| 67 |
2019 |
The WHO guidelines for chronic hepatitis B fail to detect half of the patients in need of treatment in Ethiopia. |
CHB, WHO |
| 68 |
2019 |
Wilson Disease Presenting With Acute on Chronic Liver Failure: A Single-Center Experience of Outcome and Predictors of Mortality in 68 Patients. |
ACLF, MELD, WD |
| 69 |
2019 |
[Recent advances in understanding and diagnosing hepatitis B virus infection]. |
HBcrAg, HBsAg, HBV |
| 70 |
2018 |
A multicenter pilot survey to clarify the clinical features of patients with acute-on-chronic liver failure in Japan. |
ACLF, APASL, Clif, CMA |
| 71 |
2018 |
Dual Sofosbuvir/Daclatasvir Therapy in Adolescent Patients With Chronic Hepatitis C Infection. |
CI, EOT, HCV, ITT, SOF/DCV, SVR12 |
| 72 |
2018 |
European Association for the Study of the Liver and French hepatitis C recent guidelines: The paradigm shift. |
AFEF, HCV |
| 73 |
2018 |
Expert opinion on the management of hepatitis C infection in Kuwait. |
AASLD, HCV, KHC |
| 74 |
2018 |
Late Presentation for Care Among Patients With Chronic Hepatitis C: Prevalence and Risk Factors. |
LP |
| 75 |
2018 |
Living Donor Liver Transplantation for Acute-on-Chronic Liver Failure. |
ACLF, LDLT, LT |
| 76 |
2018 |
Management of acute HCV infection in the era of direct-acting antiviral therapy. |
AASLD, DAAs |
| 77 |
2018 |
Management of chronic hepatitis B patients in immunetolerant phase: what latest guidelines recommend. |
CHB, HBeAg, HBV |
| 78 |
2018 |
Management of Chronic Hepatitis B: Knowledge and Practices of Physicians in Pakistan. |
AASLD, APASL, CHB, HBV |
| 79 |
2018 |
Radiation Segmentectomy: Potential Curative Therapy for Early Hepatocellular Carcinoma. |
HCC, RS, WHO |
| 80 |
2018 |
Radiologic criteria of response to systemic treatments for hepatocellular carcinoma. |
mRECIST, RECICL, RECIST |
| 81 |
2018 |
Rates of sustained virological response 12weeks after the scheduled end of direct-acting antiviral (DAA)-based hepatitis C virus (HCV) therapy from the National German HCV registry: does HIV coinfection impair the response to DAA combination therapy? |
DAA, HCV, SVR12 |
| 82 |
2018 |
Treatment of hepatitis C: Results in real life. |
DAAs, HCV |
| 83 |
2018 |
Well-controlled autoimmune hepatitis treatment withdrawal may be safely accomplished without liver-biopsy guidance. |
AASLD, AST |
| 84 |
2018 |
[Investigation of antinuclear antibodies in chronic hepatitis B patients]. |
AMA, ANA, ASMA, ENA, IIF, LKM |
| 85 |
2017 |
Acute-on-chronic liver failure in a multi-ethnic Asian city: A comparison of patients identified by Asia-Pacific Association for the Study of the Liver and European Association for the Study of the Liver definitions. |
ACLF, APASL |
| 86 |
2017 |
Current treatment guidelines of chronic hepatitis B: The role of nucleos(t)ide analogues and peginterferon. |
AASLD, APASL |
| 87 |
2017 |
Diagnostic Imaging of Hepatocellular Carcinoma - A Pictorial Essay. |
EORTC, HCC |
| 88 |
2017 |
Early experiences from one of the first treatment programs for chronic hepatitis B in sub-Saharan Africa. |
CHB, HBeAg, TDF |
| 89 |
2017 |
EASL International Liver Congress 2017. |
--- |
| 90 |
2017 |
EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease in severely obese people: do they lead to over-referral? |
NAFLD, NASH, NFS, TE |
| 91 |
2017 |
European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO) clinical practice recommendations for the management of non-alcoholic fatty liver disease: evaluation of their application in people with Type 2 diabetes. |
EASD, EASO |
| 92 |
2017 |
Extracellular contrast agent-enhanced MRI: 15-min delayed phase may improve the diagnostic performance for hepatocellular carcinoma in patients with chronic liver disease. |
ECA, HCC, LI-RADS, MRI |
| 93 |
2017 |
Functional hepatic imaging as a biomarker of primary and secondary tumor response to loco-regional therapies. |
ADC, CT, DCE-MRI, DWI, HAI, LRT, mRECIST, MRI, PCT, RECIST, RFA, TACE |
| 94 |
2017 |
Hepatitis C in injection drug users: It is time to treat. |
DAAs, HCV, IDUs, SVR |
| 95 |
2017 |
Ledipasvir-sofosbuvir for 6 weeks to treat acute hepatitis C virus genotype 1 or 4 infection in patients with HIV coinfection: an open-label, single-arm trial. |
HCV, SVR12 |
| 96 |
2017 |
Radioembolization for hepatocellular carcinoma: Statistical confirmation of improved survival in responders by landmark analyses. |
CI, HCC, HR, PD, RECIST 1.1, SD |
| 97 |
2017 |
Radiological response and inflammation scores predict tumour recurrence in patients treated with transarterial chemoembolization before liver transplantation. |
CR, HCC, LT, mRECIST, PLR, PR, TACE, UCSF |
| 98 |
2017 |
Response Tailored Protocol Versus the Fixed 12Weeks Course of Dual Sofosbuvir/Daclatasvir Treatment in Egyptian Patients With Chronic Hepatitis C Genotype-4 Infection: A Randomized, Open-label, Non-inferiority Trial. |
CI, ITT, PP, SOF/DCV |
| 99 |
2017 |
Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) Clinical Guideline. |
CCA, ERCP, ESGE, MRC |
| 100 |
2017 |
Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) Clinical Guideline. |
ESGE, GRADE |
|
A Search Service for Abbreviation / Long Form
